WHAT IS CLAIMED IS:

1. Use of a pharmaceutical composition unit dosage form comprising a therapeutically active agent and an absorption enhancer in the manufacture of a medicament for the treatment of a condition treatable by said therapeutically active agent, said condition being selected from the group consisting of hypoglycemia, osteoporosis, conditions associated with a bone fracture or bone defect, and hypoparathyroidism, said medicament being for concomitant oral administration of at least four of the unit dosage form, wherein said at least four of said unit dosage form are not comprised by a multi-unit dosage form and together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said therapeutically active agent is a BCS Class III agent and/or a polypeptide, and said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, and wherein at least 50 weight percents of the unit dosage form consists of said absorption enhancer.

2. The use of claim 1, wherein said medicament is for concomitant oral administration of from 4 to 10 of the unit dosage form.

3. The use according to claim 1 or 2, wherein said medicament is for increasing a Cmax and/or a bioavailability of said therapeutically active agent, as compared with a corresponding treatment by oral administration of a single unit dosage form having the same total composition as said at least four unit dosage forms.

4. The use according to any one of claims 1 to 3, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.

5. The use according to any one of claims 1 to 4, wherein said therapeutically active agent is said BCS Class III agent.

6. The use according to any one of claims 1 to 4, wherein said therapeutically active agent is said polypeptide.

7. The use according to claim 6, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof.

8. Use of a pharmaceutical composition unit dosage form comprising less than 200 µg of parathyroid hormone or a fragment thereof, and an absorption enhancer selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, wherein the unit dosage form is not comprised by a multi-unit dosage form, , in the manufacture of a medicament for the treatment of a condition treatable by said parathyroid hormone or a fragment thereof, said medicament being for concomitant oral administration of at least four of said unit dosage form, wherein said at least four of said unit dosage form together comprise a therapeutically effective amount of said parathyroid hormone or a fragment thereof and an effective amount of said absorption enhancer.

9. The use according to claim 8, wherein said condition treatable by said parathyroid hormone or a fragment thereof is selected from the group consisting of hypoparathyroidism, osteoporosis, and a medical condition associated with a bone fracture and/or bone defect.